CTNNB1 and hepatocellular carcinoma: Among the 27 patients who could be evaluated for ICIs treatment, it was found that all HCC patients with Wnt/CTNNB1 mutations were insensitive to PD-1/PD-L1 mAb, and mOSs and mPFs were lower than those without mutations.